Recombinant Mouse PD-L1 / B7-H1 Protein, Mouse IgG2a Fc Tag, low endotoxin, 100 µg

Background
Programmed cell death 1 ligand 1 (PDL1) is also known as B7-H, B7H1, MGC142294, MGC142296, PD-L1, PDCD1L1 and PDCD1LG1,which is a member of the growing B7 family of immune molecules and is involved in the regulation of cellular and humoral immune responses.PDL1 is a cell surface immunoglobulin superfamily with two Ig-like domains within the extracellular region and a short cytoplasmic domain. This protein is broadly expressed in the majority of peripheral tissues as well as hematopoietic cells. Interaction between PDL1 and its receptors belonging to the CD28 family of molecules provide both stimulatory and inhibitory signals in regulating T cell activation and tolerance. PDL1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression.

Source
Recombinant Mouse PD-L1, Mouse IgG2a Fc Tag, low endotoxin (PD1-M52A2) is expressed from human 293 cells (HEK293). It contains AA Phe 19 - Thr 238 (Accession # NP_068693).
Predicted N-terminus: Phe 19

Molecular Characterization
This protein carries a mouse IgG2a Fc tag at the C-terminus.
The protein has a calculated MW of 51.8 kDa. The protein migrates as 65-85 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 0.1 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20^°C to -70^°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Unleashing the power of immune checkpoints: Post-translational modification of novel molecules and clinical applications"
Wang, Wang, Jiang et al
Cancer Lett (2024)
(2) "The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment"
Hardaker, Sanseviero, Karmokar et al
Nat Commun (2024) 15 (1), 1700
(3) "PD-1 regulation in immune homeostasis and immunotherapy"
Gao, Shi, Xiao et al
Cancer Lett (2024)
Showing 1-3 of 28625 papers.